Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04864782
Other study ID # QL1604-301
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date September 23, 2020
Est. completion date November 1, 2023

Study information

Verified date January 2024
Source Qilu Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604) plus chemotherapy in patients with Stage IV, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus carboplatin.


Description:

The study will be conducted in 2 parts.The first stage is a single-arm clinical trial, and the second stage is a controlled clinical trial.


Recruitment information / eligibility

Status Terminated
Enrollment 46
Est. completion date November 1, 2023
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age = 18 years and = 75 years 2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 3. Life expectancy of at least 12 weeks. 4. At least one measurable lesion (according to RECIST v1.1) 5. Cervical squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma diagnosed by histopathology and confirmed by imaging as recurrent or stage ?B cervical cancer. 6. No brain metastasis, or no meningeal metastasis. 7. Patients must have normal function as defined: 1. ANC=1.5*10^9/L; PLT=90*10^9/L, Hb=90 g/L, 2. Total Bilirubin (TBIL)=1.5*Upper Limit of Normal(ULN), Alanine Transaminase (ALT)and Aspartate Aminotransferase(AST)=2.5*ULN.For liver metastasis patients, ALT and AST=5*ULN, 3. Cr= 1.5*ULN, or creatinine clearance rate =50 mL/min, 4. Proteinuria <2+,if proteinuria= 2+ and 24 hours total urine protein < 1.0 g 5. LVEF= 50%. 8. Any unresolved AEs = CTCAE Grade 1 (except alopecia). 9. Negative pregnancy test for females of child-bearing potentials. 10. Patients with reproductive function agreed to take effective contraceptive measures during the treatment and in 6 months after the end of administration. 11. Patients must be able to understand and volunteer to sign the informed consent. Exclusion Criteria: 1. Has received more than 2 courses of palliative chemotherapy for treatment of cervical cancer. 2. Has received prior chemoradiotherapy within 3 months before enrollment,or has received prior radiotherapy within 2 weaks before enrollment. 3. Has received prior surgery therapy within 2 weaks before enrollment,or has not recovered from the effects of surgery therapy. 4. Is currently participating in or has participated in a study of an investigational agent within 4 weeks before enrollment. 5. Has any active autoimmune diseases or a history of autoimmune diseases (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroid hyperfunction; patients with vitiligo; complete remission of asthma in childhood, can be included without any intervention after adulthood; asthma patients who require bronchodilators for medical intervention cannot be included). 6. Is using immunosuppressive agents or systemic hormonal therapy to achieve immunosuppressive purposes (agents amount > 10 mg / day of prednisone or other therapeutic hormones), and continue to use within 2 weeks before enrollment. 7. Known history of hypersensitivity to macromolecular protein preparation or any components of the QL1604 formulation, or any components of the study drugs. 8. Has uncontrolled clinically significant cardiac and cerebral vascular diseases within 6 months before enrollment, including but not limited to the following: myocardial infarction, severe or unstable angina, coronary artery/peripheral artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack). 9. Symptomatic congestive heart failure (New York Heart Association Grade II-IV), or NCI-CTCAE v5.0 = 2 arrhythmia, atrial fibrillation of any grade, or clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention. 10. Has active infection or an unexplained fever > 38.5°C during screening visits( subjects with tumor fever may be enrolled at the discretion of the investigator). 11. Hepatitis b surface antigen (HBsAg) positive and/or hepatitis b core antibody (HBcAb) positive and HBVDNA>103copies/ml, hepatitis c virus antibody positive . 12. Known history of human immunodeficiency virus (HIV) infection, or other acquired or congenital immunodeficiency diseases,or has a history of organ transplantation (except corneal transplantation). 13. Has been vaccinated with live anti-tumor vaccine, or have received anti-tumor immunotherapy, or may receive other systemic anti-tumor treatments during the study period. 14. Peripheral neuropathy= CTCAE Grade 2. 15. History of psychotropic substance abuse, alcoholism or drug abuse. 16. Has a clear history of neurological or mental disorders, including epilepsy or dementia. 17. Patients with other malignancies witnin 5 years( except cured basal cell carcinoma of skin cancer, papillary thyroid carcinoma). 18. At the discretion of the investigator, there are patients with serious concomitant disease that compromises patient safety or affects the patient's completion of the study,such as unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 160 mmHg, diastolic blood pressure > 110 mmHg), serious diabetes, thyroid diseases, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
QL1604
Intravenous Infusion
Paclitaxel injection
Intravenous Infusion
Cisplatin/Carboplatin
Intravenous Infusion

Locations

Country Name City State
China Sun Yat-Sen University Cancer Center Guangzhou Guangzhou

Sponsors (1)

Lead Sponsor Collaborator
Qilu Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with adverse events The incidence and severity of adverse events (AE),serious adverse events (SAE) and treatment-emergent adverse events (TEAEs) according to CTCAE V5.0 Up to 90 days from last dose
Primary Objective response rate (ORR) as assessed by investigator based on RECIST v1.1 and iRECIST Objective response rate (ORR) as assessed by investigator based on RECIST v1.1 and iRECIST approximately 2 years
Secondary Progression-free survival (PFS) as assessed by investigator based on RECIST v1.1 and iRECIST Progression-free survival (PFS) is defined as time from the date of randomization to the date of first documentation of disease progression or death due to any cause(whichever occurs earlier) approximately 2 years
Secondary Overall survival(OS) Overall survival(OS) is defined as the time from randomization to death due to any cause approximately 2 years
Secondary Duration of response(DOR) Duration of response(DOR) as assessed by investigator based on RECIST v1.1 and iRECIST approximately 2 years
Secondary Time to progress (TTP) Time to progress (TTP) as assessed by investigator based on RECIST v1.1 and iRECIST approximately 2 years
Secondary AUC of QL1604 Area under curve from zero to infinity approximately 1 years
Secondary Cmax of QL1604 Peak concentration approximately 1 years
Secondary Cmin of QL1604 The trough value at steady state approximately 1 years
Secondary Tmax of QL1604 Time to Cmax approximately 1 years
Secondary T1/2 of QL1604 Half life approximately 1 years
Secondary Vss of QL1604 Steady-state apparent volume of distribution based on plasma concentration approximately 1 years
Secondary CLT(total body clearance) of QL1604 Total body clearance approximately 1 years
Secondary Immunogenicity The titer of anti-drug antibodies (ADA)and neutralizing antibodies(Nab) approximately 1 years
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A
Completed NCT02420665 - Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia Early Phase 1